Skip to content

Jeffrey Trocio

  • Global Health & Value - Outcomes & Evidence
  • Pfizer Inc
  • 12h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 651CitationsNumber of citations received by Jeffrey's publications. Updated daily.

Other IDs

Research interests

observationalpatient reported outcomesproanticoagulationcardiovascularceroabnoacatrial fibrillationhiv

Co-authors (165)

Publications (5)

  • All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants

    • Deitelzweig S
    • Luo X
    • Gupta K
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Estimated prevalence of undiagnosed atrial fibrillation in the United States

    • Turakhia M
    • Shafrin J
    • Bognar K
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States

    • Deitelzweig S
    • Evans M
    • Trocio J
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan

    • Amin A
    • Keshishian A
    • Vo L
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation

    • Kocis P
    • Liu G
    • Makenbaeva D
    • et al.
    N/AReaders
    0Citations
    Get full text

Professional experience

Global Health & Value - Outcomes & Evidence

Pfizer Inc.

October 2006 - Present